{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:42:37Z","timestamp":1787686957634,"version":"build-2784847793"},"reference-count":24,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.1182\/bloodadvances.2025018546","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T21:22:58Z","timestamp":1767820978000},"page":"1947-1951","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed\/refractory follicular lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"first","affiliation":[{"name":"1Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain"},{"name":"2Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"3Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8549-7409","authenticated-orcid":false,"given":"Emil Rams\u00f8","family":"Kyvsgaard","sequence":"additional","affiliation":[{"name":"4Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-4605","authenticated-orcid":false,"given":"V\u00edctor","family":"Navarro Garc\u00e9s","sequence":"additional","affiliation":[{"name":"5Statistics Unit, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-2247","authenticated-orcid":false,"given":"David A.","family":"Russler-Germain","sequence":"additional","affiliation":[{"name":"6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-5877","authenticated-orcid":false,"given":"Katharine","family":"Lewis","sequence":"additional","affiliation":[{"name":"7Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Mart\u00edn Garc\u00eda-Sancho","sequence":"additional","affiliation":[{"name":"8Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, University of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2765-1113","authenticated-orcid":false,"given":"Itziar","family":"Carro","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9423-1941","authenticated-orcid":false,"given":"Dylan","family":"Therwhanger","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Quintela","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Instituto Catal\u00e1n de Oncolog\u00eda-Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras-Hospital Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9289-1335","authenticated-orcid":false,"given":"Matthew","family":"Ku","sequence":"additional","affiliation":[{"name":"13Department of Hematology, St Vincent\u2019s Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2412-0408","authenticated-orcid":false,"given":"Pilar","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5998-6925","authenticated-orcid":false,"given":"Evelyn","family":"Valencia","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Vega","sequence":"additional","affiliation":[{"name":"16Department of Hematology, University Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9431-4646","authenticated-orcid":false,"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-9634","authenticated-orcid":false,"given":"Angel","family":"Serna","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain"},{"name":"2Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"3Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-1173","authenticated-orcid":false,"given":"Simon","family":"Husby","sequence":"additional","affiliation":[{"name":"4Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0121","authenticated-orcid":false,"given":"Beatriz","family":"De La Cruz","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luan","sequence":"additional","affiliation":[{"name":"6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3229-9003","authenticated-orcid":false,"given":"Sergi","family":"Camarillas","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5081-8466","authenticated-orcid":false,"given":"Luc\u00eda","family":"Medina","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Cabero","sequence":"additional","affiliation":[{"name":"8Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, University of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"16Department of Hematology, University Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6550-2621","authenticated-orcid":false,"given":"Miguel","family":"Canales","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Instituto Catal\u00e1n de Oncolog\u00eda-Instituto de Investigaci\u00f3n contra la Leucemia Josep Carreras-Hospital Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain"},{"name":"2Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"3Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen","family":"Schuster","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"7Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"4Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark"},{"name":"19Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain"},{"name":"2Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"3Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain"},{"name":"2Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"3Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"6","key":"2026032014070591000_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026032014070591000_bib2","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026032014070591000_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"17","key":"2026032014070591000_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026032014070591000_bib5","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"2026032014070591000_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026032014070591000_bib7","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2024-197897","article-title":"Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study","volume":"144","author":"Shadman","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026032014070591000_bib8","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2024-207895","article-title":"Real-world management patterns of acute toxicity following bispecific antibody therapy for patients with B-cell lymphoma - the Geltamo (Spanish Lymphoma Group) experience","volume":"144","author":"Bastos-Oreiro","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026032014070591000_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026032014070591000_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026032014070591000_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"14","key":"2026032014070591000_bib12","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results From the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026032014070591000_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.27548","article-title":"Outcomes of CD19 CAR T in transformed indolent lymphoma compared to de novo aggressive large B-cell lymphoma","volume":"100","author":"Thiruvengadam","year":"2025","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026032014070591000_bib14","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2024-199799","article-title":"Prior bendamustine (benda) exposure did not impact clinical outcomes and decreased CD4+ but not CD8+ T-cells in patients with diffuse large B-cell lymphoma (DLBCL) treated with the bispecific antibody epcoritamab (epcor)","volume":"144","author":"Phillips","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026032014070591000_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2024-200369","article-title":"Fixed-duration epcoritamab in combination with bendamustine + rituximab for first-line treatment of follicular lymphoma: initial results from Epcore NHL-2 arm 3","volume":"144","author":"Brody","year":"2024","journal-title":"Blood"},{"issue":"9873","key":"2026032014070591000_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"2026032014070591000_bib17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026032014070591000_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"2026032014070591000_bib19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2026032014070591000_bib20","doi-asserted-by":"crossref","first-page":"e008338","DOI":"10.1136\/jitc-2023-008338","article-title":"Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"12","author":"Brouwer-Visser","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"15","key":"2026032014070591000_bib21","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"2026032014070591000_bib22","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1182\/blood.2025029117","article-title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","volume":"146","author":"Brooks","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026032014070591000_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026032014070591000_bib24","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1947\/2508169\/blooda_adv-2025-018546-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1947\/2508169\/blooda_adv-2025-018546-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:07:15Z","timestamp":1774030035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/1947\/565890\/Impact-of-prior-bendamustine-exposure-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018546","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,12]]}}}